| Biomarker ID | 435 |
| PMID | 19242826 |
| Year | 2010 |
| Biomarker | KLK11 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated (CS: (1-2) 6.05 ± 1.34 vs CS 3: 3.93 ± 0.45) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:- Collagen chain trimerization, MSP-RON Signaling |
| Experiment | Clincal Stage (1-2) Vs Clinical Stage 3 |
| Type of Biomarker | Prognostic |
| Cohort | Out of 63 patients, 39 had Clinical stages (1-2) and 24 had Stage 3. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.009 |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | Results were then normalized using the ratio of TMPRSS2/ b-actin and KLK11/b-actin concentration for each sample |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | KLK11 |